Metabolic research peptides

The metabolic peptide class spans three mechanistically distinct pharmacological spaces: incretin-pathway GLP-1/GIP/glucagon-receptor agonists (semaglutide, tirzepatide, retatrutide) that dominate contemporary obesity and diabetes treatment; AMPK-pathway compounds (MOTS-c, 5-Amino-1MQ) addressing cellular energy metabolism; and hGH-fragment lipolytic agents (AOD-9604) targeting adipose tissue directly.

The metabolic pharmacology space has been transformed in the late 2020s by the incretin-mimetic peptide class, whose clinical impact on type-2 diabetes and obesity has been the most significant therapeutic development in metabolic disease since insulin. The research peptide framework spanning this space covers three mechanistically orthogonal pathways. The incretin pathway drives appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying through GLP-1 receptor and GIP receptor engagement — the mechanistic basis of MHRA-licensed semaglutide (Ozempic/Wegovy/Rybelsus) and tirzepatide (Mounjaro/Zepbound). The AMPK pathway drives insulin-independent glucose disposal, fatty acid oxidation, and mitochondrial biogenesis — the domain of the mitochondrial-derived peptide MOTS-c and (mechanistically overlapping) metformin and exercise. The lipolytic pathway addresses adipose tissue directly — the AOD-9604 hGH-fragment mechanism. These pathways address different cellular targets with mechanistically complementary rather than redundant pharmacology. The incretin pharmacology dominates commercial and research interest. Native GLP-1 has a plasma half-life of approximately two minutes due to rapid dipeptidyl peptidase-4 (DPP-4) degradation; all clinically successful GLP-1R agonists solve this through engineering. Semaglutide incorporates α-aminoisobutyric acid at position 8 (blocking DPP-4 cleavage) and covalent C18 fatty diacid attachment to lysine 26 (enabling serum albumin binding for ~7-day half-life supporting once-weekly subcutaneous dosing). Tirzepatide extends this to dual GLP-1R/GIPR agonism through a GIP-based chimeric backbone with GLP-1R cross-reactivity, achieving materially larger HbA1c reduction and weight loss versus semaglutide in head-to-head SURPASS-2 and SURMOUNT-5 trials. Retatrutide (currently Phase III TRIUMPH programme, not yet licensed) extends this further to triple GLP-1R/GIPR/glucagon-receptor agonism, adding an energy-expenditure component to appetite suppression that produced 24.2% mean weight loss over 48 weeks in Phase II. The glucagon-receptor addition is mechanistically counterintuitive but pharmacologically synergistic — the GLP-1R-driven glucose-dependent insulin secretion counter-balances glucagon's hepatic glucose mobilisation, unlocking glucagon's energy-expenditure benefits without hyperglycaemia. The AMPK and lipolytic pathways operate on completely different targets. MOTS-c is a 16-amino-acid endogenous peptide encoded within the mitochondrial 12S rRNA gene (the founding mitochondrial-derived peptide discovered by Cohen at USC in 2015). It activates AMPK signalling partly through folate-cycle modulation, producing effects on fatty acid oxidation, GLUT4 translocation, and mitochondrial biogenesis distinct from incretin pharmacology. 5-Amino-1MQ (a small molecule NNMT inhibitor, not strictly a peptide but grouped with metabolic research compounds) restores cellular SAM and NAD+ pools by inhibiting the NNMT enzyme that becomes pathologically overexpressed in obese adipose tissue. AOD-9604, the C-terminal hGH fragment 177-191, produces lipolysis and reduced fat mass without measurable IGF-1 elevation or insulin desensitisation. Standard endpoints for metabolic peptide research include fasting glucose and HbA1c for glycaemic control, fasting insulin and C-peptide with HOMA-IR for insulin sensitivity, oral glucose tolerance test (OGTT) or mixed-meal tolerance test (MMTT) for incretin-effect characterisation, body composition by DEXA (lean vs fat mass distribution), CT or MRI for visceral adipose tissue volume, lipid panel and apolipoproteins, inflammatory markers (hsCRP, IL-6), cardiovascular endpoints (BP, heart rate, echocardiographic function in chronic studies), and hepatic endpoints in NAFLD/MASH contexts (hepatic fat by MR spectroscopy, ALT/AST/GGT, ELF panel). UK regulatory status ranges across the class. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are fully MHRA-licensed with NICE technology appraisal (TA664, TA875, TA924, TA1026) supporting NHS prescription within specified eligibility criteria. Retatrutide is Phase III unlicensed. AOD-9604 has completed Phase IIb obesity trials but did not proceed to registration. MOTS-c and 5-Amino-1MQ are research-chemical status. Notably, none of the incretin class is currently on the WADA Prohibited List as of 2026 — a substantial contrast to the GH-axis peptides which are uniformly S2-prohibited. Recreational athletic use of licensed incretins raises ethical questions but is not a doping violation.

Peptides in this category